Monitoring Steroid Replacement Therapy in Children with Congenital Adrenal Hyperplasia
Overview
Pediatrics
Affiliations
Background: The objective of this study was to compare the analysis of 17-hydroxyprogesterone (17-OHP) by radio-immunoassay (RIA) in serum with analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS) on dried blood spot samples (DBSS) for monitoring therapy in children with congenital adrenal hyperplasia (CAH), and to investigate differences in 17-OHP values during the day.
Methods: Fourteen children (8 females), median age 4.2 (0.3-16.0) years, were studied. Serum samples and DBSS were drawn before hydrocortisone dosing.
Results: 17-OHP by LC-MS/MS in DBSS were highly correlated to 17-OHP by RIA in serum, r=0.956, p<0.01. A total of 26 three-time-point series were investigated. Using only the afternoon 17-OHP values to determine the hydrocortisone doses would have led to overdosing seven times and underdosing six times.
Conclusions: Good agreement was demonstrated between 17-OHP determination by RIA in serum and LC-MS/MS on DBSS. Multiple 17-OHP measurements per day are required to ensure sufficient hydrocortisone dose adjustment.
Monitoring treatment in pediatric patients with 21-hydroxylase deficiency.
Itonaga T, Hasegawa Y Front Endocrinol (Lausanne). 2023; 14:1102741.
PMID: 36843618 PMC: 9945343. DOI: 10.3389/fendo.2023.1102741.
Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry.
Lawrence N, Bacila I, Dawson J, Bryce J, Ali S, van den Akker E Clin Endocrinol (Oxf). 2022; 97(5):551-561.
PMID: 35781728 PMC: 9796837. DOI: 10.1111/cen.14796.
Adriaansen B, Kamphuis J, Schroder M, Olthaar A, Bock C, Brandt A Clin Endocrinol (Oxf). 2022; 97(1):36-42.
PMID: 35150157 PMC: 9542109. DOI: 10.1111/cen.14690.
Schroder M, van Herwaarden A, Span P, van den Akker E, Bocca G, Hannema S J Clin Endocrinol Metab. 2021; 107(4):e1661-e1672.
PMID: 34788830 PMC: 8947312. DOI: 10.1210/clinem/dgab826.